NCT02498613
Breast Cancer Type: Triple Negative
Hormone Mutations:
Other Mutations:
Breast Cancer Tissue:
Recruitment Status: Active, not recruiting
Phase 2
Drug Category: Tyrosine-Kinase Inhibitor, Misc Inhibitor
Key Eligibility Criteria:
Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases:
Additional Notes:
Exclusions: Patients with untreated or symptomatic brain metastases
https://ClinicalTrials.gov/show/NCT02498613